Search Result
Results for "
<i>Cerasus yedoensis<_i> (Mats.) Y� et Li
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N10103
-
|
Others
|
Others
|
Neoschaftoside is a natural product that can be isolated from Viola yedoensis .
|
-
-
- HY-170500
-
-
-
- HY-N12269
-
|
Others
|
Others
|
Madolin U is a germacrane sesquiterpene isolated from the herb of Viola yedoensis .
|
-
-
- HY-N12265
-
|
Others
|
Inflammation/Immunology
|
Versicolactone B is a sesquiterpene that can be isolated from Viola yedoensis. Versicolactone B exhibits anti-complement activity against the classical pathway and the alternative pathway .
|
-
-
- HY-149915
-
-
-
- HY-170503
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-20 (Compound A49) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC50 ≤50 nM. MAT2A-IN-20 inhibits human UGT1A1 with an IC50 of 28.45 μM. MAT2A-IN-20 exhibits antitumor in mouse models .
|
-
-
- HY-162135
-
|
Methionine Adenosyltransferase (MAT)
Reactive Oxygen Species
|
Cancer
|
MAT2A-IN-14 (compound H3) is a MAT2A inhibitor, and generates reactive oxygen species after sonication to specifically degrade cellular MAT2A via rapid oxidative reactions. Combination of MAT2A-IN-14 and sonication induces 87% MAT2A depletion in human colon cancer cell .
|
-
-
- HY-170905S
-
-
-
- HY-161298
-
-
-
- HY-168445
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-21 (compound 28) is a potent methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 49 nM. MAT2A-IN-21 selectivity inhibits MTAP-deficient cancer cells .
|
-
-
- HY-144185
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .
|
-
-
- HY-144184
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .
|
-
-
- HY-144181
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .
|
-
-
- HY-142929
-
|
Somatostatin Receptor
|
Cancer
|
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .
|
-
-
- HY-142928
-
|
Somatostatin Receptor
|
Cancer
|
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .
|
-
-
- HY-142930
-
|
Somatostatin Receptor
|
Cancer
|
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .
|
-
-
- HY-162010
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile.
MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research .
|
-
-
- HY-144179
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer .
|
-
-
- HY-173281
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a). The IC50 value for the inhibition of MAT2a is 20 nM, and the IC50 value for the antiproliferative activity against HAP1MTAP–/– cells is 10 nM. MAT2A-IN-24 can be used in the research field of tumor diseases associated with MTAP deficiency .
|
-
-
- HY-170906S
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC50 of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP −/−) and in the HCT-116 WT cell line with IC50s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP −/−) and in the HCT-116 WT cell line with IC50s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP −/−) cell proliferation with with an IC50 of 47 nM .
|
-
-
- HY-155148
-
-
-
- HY-170501
-
-
-
- HY-170502
-
-
-
- HY-170421
-
-
-
- HY-112569
-
-
-
- HY-139536
-
-
-
- HY-163656
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A inhibitor 5(compound 39) is an orally active, selectivity and blood-brain permeability inhibitor of MAT2A with the IC50 of 11 nM. MAT2A inhibitor 5 inhibits tumor cell growth in vivo .
|
-
-
- HY-139139
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC50 of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers .
|
-
-
- HY-155149
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP -/- cell line) .
|
-
-
- HY-159156
-
|
Methionine Adenosyltransferase (MAT)
Apoptosis
Fluorescent Dye
|
Cancer
|
MAT2A inhibitor 6 (Compound 3N-h) is a specific MAT2A inhibitor with oral activity and yellow fluorescence (IC50=26 nM), capable of visualizing MAT2A both in vitro and in vivo (λex = 430 nm, λem = 585 nm). MAT2A inhibitor 6 can induce apoptosis and has anticancer activity, which can be used in cancer research .
|
-
-
- HY-158143
-
-
-
- HY-RS08167
-
|
Small Interfering RNA (siRNA)
|
Others
|
MAT2A Human Pre-designed siRNA Set A contains three designed siRNAs for MAT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
MAT2A Human Pre-designed siRNA Set A
MAT2A Human Pre-designed siRNA Set A
-
- HY-RS20986
-
|
Small Interfering RNA (siRNA)
|
Others
|
Mat1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Mat1a Mouse Pre-designed siRNA Set A
Mat1a Mouse Pre-designed siRNA Set A
-
- HY-RS23017
-
|
Small Interfering RNA (siRNA)
|
Others
|
Mat2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Mat2a Rat Pre-designed siRNA Set A
Mat2a Rat Pre-designed siRNA Set A
-
- HY-RS27503
-
|
Small Interfering RNA (siRNA)
|
Others
|
Mat1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Mat1a Rat Pre-designed siRNA Set A
Mat1a Rat Pre-designed siRNA Set A
-
- HY-RS08166
-
|
Small Interfering RNA (siRNA)
|
Others
|
MAT1A Human Pre-designed siRNA Set A contains three designed siRNAs for MAT1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
MAT1A Human Pre-designed siRNA Set A
MAT1A Human Pre-designed siRNA Set A
-
- HY-RS16583
-
|
Small Interfering RNA (siRNA)
|
|
Mat2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Mat2a Mouse Pre-designed siRNA Set A
Mat2a Mouse Pre-designed siRNA Set A
-
- HY-RS27504
-
|
Small Interfering RNA (siRNA)
|
Others
|
Mat2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Mat2b Rat Pre-designed siRNA Set A
Mat2b Rat Pre-designed siRNA Set A
-
- HY-RS08168
-
|
Small Interfering RNA (siRNA)
|
Others
|
MAT2B Human Pre-designed siRNA Set A contains three designed siRNAs for MAT2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
MAT2B Human Pre-designed siRNA Set A
MAT2B Human Pre-designed siRNA Set A
-
- HY-RS20987
-
|
Small Interfering RNA (siRNA)
|
Others
|
Mat2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Mat2b Mouse Pre-designed siRNA Set A
Mat2b Mouse Pre-designed siRNA Set A
-
- HY-136144
-
FIDAS-5
3 Publications Verification
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities .
|
-
-
- HY-136145
-
|
Wnt
|
Cancer
|
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities .
|
-
-
- HY-107778
-
-
-
- HY-112131
-
-
-
- HY-138630
-
-
-
- HY-169257
-
-
-
- HY-P4129
-
|
nAChR
|
Others
|
Rabies Virus Matrix Protein Fragment (RV-MAT) is a polypeptide. Rabies Virus Matrix Protein Fragment targets the acetylcholine receptor (AChR) that exists on the cell surface .
|
-
-
- HY-162353
-
-
-
- HY-157154
-
|
SARS-CoV
|
Infection
|
MAT-POS-e194df51-1 is an orally active, non-covalent and non-peptide SARS-CoV-2 main protease (M pro) inhibitor with an IC50 value of 37nM. MAT-POS-e194df51-1 is cytotoxic with EC50 values of 64 nM and 126 nM in A549-ACE2-TMPRSS2 cells and HeLa -ACE2 cells, respectively .
|
-
-
- HY-W763806
-
|
Biochemical Assay Reagents
|
Others
|
Zein is a plant protein‐based polymer, can be used to prepare nanofibrous mats through electrospun. Zein has good cell compatibility and easy fabrication ability, and can be used in drug delivery systems .
|
-
- HY-101257
-
|
CDK
|
Cancer
|
YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
|
-
- HY-145778
-
|
Somatostatin Receptor
|
Neurological Disease
|
AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-41998 is a brain-penetrant compound. AGI-41998 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .
|
-
- HY-101257B
-
|
CDK
|
Cancer
|
YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
|
-
- HY-145777
-
|
Somatostatin Receptor
|
Neurological Disease
Cancer
|
AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .
|
-
- HY-N8639
-
|
Others
|
Others
|
Chrysin 8-C-β-D-glucoside is a natural compound isolated from the herbs of Psidium guajava .
|
-
- HY-112130
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC50 of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer .
|
-
- HY-108331
-
-
Cat. No. |
Product Name |
Type |
-
- HY-W763806
-
|
Native Proteins
|
Zein is a plant protein‐based polymer, can be used to prepare nanofibrous mats through electrospun. Zein has good cell compatibility and easy fabrication ability, and can be used in drug delivery systems .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4129
-
|
nAChR
|
Others
|
Rabies Virus Matrix Protein Fragment (RV-MAT) is a polypeptide. Rabies Virus Matrix Protein Fragment targets the acetylcholine receptor (AChR) that exists on the cell surface .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-170905S
-
|
MAT2A-IN-22 (Compound 29-1) is a BBB-penatrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .
|
-
-
- HY-170906S
-
|
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC50 of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP −/−) and in the HCT-116 WT cell line with IC50s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP −/−) and in the HCT-116 WT cell line with IC50s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP −/−) cell proliferation with with an IC50 of 47 nM .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-RS08167
-
|
|
siRNAs
Human Pre-designed siRNA Sets
|
MAT2A Human Pre-designed siRNA Set A contains three designed siRNAs for MAT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS20986
-
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
Mat1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS23017
-
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
Mat2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS27503
-
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
Mat1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS08166
-
|
|
siRNAs
Human Pre-designed siRNA Sets
|
MAT1A Human Pre-designed siRNA Set A contains three designed siRNAs for MAT1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS16583
-
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
Mat2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS27504
-
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
Mat2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS08168
-
|
|
siRNAs
Human Pre-designed siRNA Sets
|
MAT2B Human Pre-designed siRNA Set A contains three designed siRNAs for MAT2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS20987
-
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
Mat2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: